Antibiotic use after a typhoid conjugate vaccine: factors beyond vaccination in low-income countries

Lancet Glob Health. 2023 Sep;11(9):e1325-e1326. doi: 10.1016/S2214-109X(23)00365-0.

Authors

Tapfumanei Mashe¹, Mateusz Hasso-Agopsowicz², Blessmore V Chaibva³

Affiliations

¹ One Health Office, Ministry of Health and Child Care, Harare, Zimbabwe; Health System Strengthening Unit, World Health Organization, Harare, Zimbabwe. Electronic address: mashet2006@yahoo.co.uk.
² Vaccine Product Delivery Research, Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland.
³ Ministry of Health and Child Care, Directorate of Pharmacy, Harare, Zimbabwe.

PMID: 37591573
DOI: 10.1016/S2214-109X(23)00365-0

No abstract available

Publication types

Comment

MeSH terms

Humans
Typhoid Fever* / epidemiology
Typhoid Fever* / prevention & control
Typhoid-Paratyphoid Vaccines*
Vaccination
Vaccines, Conjugate

Substances

Typhoid-Paratyphoid Vaccines
Vaccines, Conjugate

Grants and funding

001/WHO_/World Health Organization/International